Skip to main content

Market Overview

Selecta Biosciences/Asklepios Start Early-Stage Study To Assess ImmTOR In Gene Therapy

  • Selecta Biosciences Inc (NASDAQ: SELB) and Asklepios BioPharmaceutical, a subsidiary of Bayer AG (OTCMKTS: BAYRY), have initiated a Phase 1 dose-escalation trial evaluating SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) without DNA, combined with ImmTOR.
  • The trial aims to determine the optimal dose of ImmTOR to mitigate antibodies' formation to AAV8 capsids used in gene therapies.
  • The 45-healthy volunteer trial is designed to evaluate the safety and preliminary efficacy of ImmTOR in gene therapy. Preliminary efficacy will be measured by assessing levels of AAV8-specific neutralizing antibodies.
  • Initial results are expected by the end of this year.
  • Price Action: SELB gained 2.99% at $4.82, while BAYRY shares are down 1.48% at $16.30 on the last check Wednesday.

Related Articles (BAYZF + SELB)

View Comments and Join the Discussion!

Posted-In: gene therapy Phase 1 TrialBiotech News Penny Stocks Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at